california dmhc glp-1 coverage exclusion allowed is ending for weight loss drugs, despite TrumpRx Governor's 2025-26 May Revision Proposes
Description
McCrory, M
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese adults with obesity achieved the 24-week primary endpoint
Bullock BP, Heller RS, and Habener JF
Always consult your healthcare provider before starting any new medication or wellness regimen
Medications that mimic this hormone help enhance these natural signals, which can lead to reduced appetite, improved blood sugar control, and better portion awareness
